The Impact of Comorbidities on the Outcomes of Egyptian COVID-19 Patients: A Follow-Up Study

Table 2

Distribution of the studied groups according to outcome of hospitalization.

	Outcome of hospitalization (over 30 days)				value
	Died (28)		Survived (120)
	N	(%)	N	(%)
Gender
Male	16	57.1	69	57.5	0.97
Female	12	42.9	51	42.5
Age
<18 y	3	10.7	27	22.5	0.17
18 y	12	42.9	57	47.5
≥60 y	13	46.4	36	30.0
Symptoms
History of fever	11	39.3	81	67.5	0.006
Conjunctival congestion	12	42.9	10	8.3	<0.001
Nasal congestion	16	57.1	24	20.0	<0.001
Headache	24	85.7	65	54.2	0.002
Cough	28	100	76	63.3	<0.001
Sore throat	28	100	73	60.8	<0.001
Sputum production	0	0.0	5	4.2	0.58
Fatigue	28	100	60	50.0	<0.001
Shortness of breath	28	100	47	39.2	<0.001
Nausea	8	28.6	18	15.0	0.089
Vomiting	4	14.3	10	8.3	0.30
Diarrhea	0	0.0	5	4.2	0.58
Myalgia	16	57.1	16	13.3	<0.001
Cyanosis	4	14.3	0	0.0	0.001
Complications
Pneumonia	12	42.9	13	10.8	<0.001
ARDS	28	100	0	0.0	<0.001

Significant at . Significant at . CT: computerized topography.